NMT

Pacylex Pharmaceuticals Reports Phase 1 Safety and Efficacy Results for Zelenirstat in Colorectal and other Cancers

Retrieved on: 
Wednesday, January 17, 2024

Today Pacylex announced that the results of its Phase 1 dose escalation safety and tolerability study for zelenirstat, an investigational NMT inhibitor and Pacylex's lead product candidate, in refractory/ relapsed colorectal and other cancers, will be presented January 20, 2024, at the upcoming ASCO Gastrointestinal Cancers Symposium.

Key Points: 
  • Today Pacylex announced that the results of its Phase 1 dose escalation safety and tolerability study for zelenirstat, an investigational NMT inhibitor and Pacylex's lead product candidate, in refractory/ relapsed colorectal and other cancers, will be presented January 20, 2024, at the upcoming ASCO Gastrointestinal Cancers Symposium.
  • Pacylex presents zelenirstat results in gastrointestinal and other cancer patients at the ASCO Gastrointestinal Cancers Symposium on January 18-20, 2024, in San Francisco, CA.
  • Zelenirstat prolonged progression free survival in gastrointestinal and other cancer patients in Phase 1 at the recommended Phase 2 dose.
  • An advanced colorectal cancer patient relapsed from 7 prior lines of therapy, has seen reductions of approximately 50% in CEA and tumor volumes so far with zelenirstat.

Groundbreaking Linguistic AI Solution ‘Evolve’ by RWS Transforms Global Translation Practices

Retrieved on: 
Thursday, January 25, 2024

Following a successful beta program involving Dell and several other industry leaders, RWS announces the availability of Evolve , a groundbreaking linguistic AI solution which offers significant efficiency gains for global enterprises with substantial translation demands.

Key Points: 
  • Following a successful beta program involving Dell and several other industry leaders, RWS announces the availability of Evolve , a groundbreaking linguistic AI solution which offers significant efficiency gains for global enterprises with substantial translation demands.
  • During the beta program, RWS has enhanced Evolve through using client feedback and by adding its own translation management system to the solution.
  • “RWS has created a groundbreaking linguistic AI solution that addresses the ever-growing translation challenges presented by large content volumes, enabling us to engage international audiences faster.”
    The Evolve linguistic AI solution is currently available in several language pairs – with more to come in 2024.
  • Translation management system (TMS): facilitates end-to-end localization processes and workflows across all content types, repositories, translation methods and stakeholder groups.

Searchlight Cyber Introduces AI-Powered Language Translation to Decipher the Dark Web

Retrieved on: 
Wednesday, January 24, 2024

Searchlight Cyber , the dark web intelligence company, has added AI-powered language translation into its dark web investigation and monitoring products DarkIQ and Cerberus .

Key Points: 
  • Searchlight Cyber , the dark web intelligence company, has added AI-powered language translation into its dark web investigation and monitoring products DarkIQ and Cerberus .
  • The inability to translate and interpret dark web data in other languages hinders law enforcement and cybersecurity teams’ capacity to detect, understand, and accurately respond to emerging dark web threats.
  • Unlike conventional translation tools, Searchlight’s AI in-platform translation tool excels at accurately translating specialized dark web slang, particularly in Russian, which accounts for 66% of all non-English content on the dark web.
  • Dark web translation will form part of the Searchlight Cyber AI suite of cybersecurity tools launching in 2024.

Pacylex Pharmaceuticals Reports Safety and Efficacy Results from Its Phase 1 First-In-Human Study of Zelenirstat (PCLX-001)

Retrieved on: 
Friday, December 1, 2023

To view the full announcement, including downloadable images, bios, and more, click here .

Key Points: 
  • To view the full announcement, including downloadable images, bios, and more, click here .
  • Phase 1 safety and tolerability of zelenirstat was acceptable and a recommended Phase 2 dose was established.
  • Zelenirstat unexpectedly prolonged progression free survival in solid tumor patients in Phase 1 at the recommended Phase 2 dose.
  • Pacylex will report Phase 1 safety results and potential efficacy signals at upcoming life science investment conferences in December 2023 and January 2024.

Enhanced Potential of Myricx’s NMT Inhibitor Payloads with Dual Senolytic and Cytotoxic Modes of Action as ADC Cancer Therapies

Retrieved on: 
Monday, November 27, 2023

Senescent, or so called ‘zombie’ cells, can have deleterious effects on tissue function as they are persistent and secrete many proteins.

Key Points: 
  • Senescent, or so called ‘zombie’ cells, can have deleterious effects on tissue function as they are persistent and secrete many proteins.
  • Small-molecule drugs that selectively eliminate senescent cells, known as senolytics, provide a promising novel strategy for treating multiple diseases, including cancer, fibrotic diseases, and age-related conditions.
  • Overall, the study demonstrated that senescent cells rely on a hyperactive secretory apparatus and that this secretory phenotype is dependent on NMT and inhibiting NMT kills senescent cells.
  • Combined with the cytotoxic effect of NMTis, the senolytic mechanism has the potential to induce deeper and more durable responses in treating tumours than purely cytotoxic payloads.

Myricx Bio Enters into an Exclusive Antibody License Agreement with WuXi Biologics

Retrieved on: 
Tuesday, November 21, 2023

Myricx intends to progress the ADC through preclinical and clinical development for difficult-to-treat solid tumours.

Key Points: 
  • Myricx intends to progress the ADC through preclinical and clinical development for difficult-to-treat solid tumours.
  • WuXi Bio will receive an upfront payment and will be eligible for development and commercialisation milestone payments, as well as royalties on net sales.
  • This is the second antibody license agreement that Myricx has entered into with a global company in the past few months as the Company builds out its pipeline of NMTi-ADCs.
  • Myricx CEO Dr Robin Carr said, “We are delighted to have reached this agreement with WuXi Bio, one of the top biologics CRDMOs globally.

Myricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of Directors

Retrieved on: 
Wednesday, November 15, 2023

Dr Martin is a renowned biotech company founder, director and entrepreneur, and a pioneer and leader in the ADC space.

Key Points: 
  • Dr Martin is a renowned biotech company founder, director and entrepreneur, and a pioneer and leader in the ADC space.
  • Dr Martin was instrumental in co-founding ADC Therapeutics (NYSE: ADCT) in Jan 2012 and served as its CEO since inception until May 2022.
  • Alongside his role as Chairman of Myricx, he is also Chairman of the Board of Tokamak Energy Ltd, and Tagworks Pharmaceuticals BV, and a Director on the Board of Osivax SAS.
  • Dr Robin Carr, Myricx CEO and Board Director, said, “We are thrilled that Chris has joined our Board and taken on the role of Chairman.

Board Announces Removal of Merger Proposals from Annual Meeting Agenda

Retrieved on: 
Thursday, October 19, 2023

The Boards of Trustees of Nuveen New Jersey Quality Municipal Income Fund (NYSE:NXJ) and Nuveen Quality Municipal Income Fund (NYSE:NAD) as well as Nuveen Massachusetts Quality Municipal Income Fund (NYSE:NMT) and Nuveen AMT-Free Quality Municipal Income Fund (NYSE:NEA) announce the removal of a previously approved merger proposal from each funds’ upcoming shareholder meeting agenda.

Key Points: 
  • The Boards of Trustees of Nuveen New Jersey Quality Municipal Income Fund (NYSE:NXJ) and Nuveen Quality Municipal Income Fund (NYSE:NAD) as well as Nuveen Massachusetts Quality Municipal Income Fund (NYSE:NMT) and Nuveen AMT-Free Quality Municipal Income Fund (NYSE:NEA) announce the removal of a previously approved merger proposal from each funds’ upcoming shareholder meeting agenda.
  • Previously, the Board of Trustees of each respective fund approved the merger of NXJ into NAD and the merger of NMT into NEA.
  • The Boards of Trustees of each fund considered current market conditions and other relevant considerations for each fund in assessing whether to move forward with the proposed merger.
  • It was determined that the proxy solicitation process and its associated costs would not be in the best interests of each fund’s shareholders, therefore resulting in the removal of the merger proposal from the upcoming shareholder meeting agendas.

Myricx Bio to Present Preclinical Data Validating NMTi as a Novel ADC Payload Class

Retrieved on: 
Tuesday, October 17, 2023

Myricx’s payload platform is based on proprietary potent small molecule NMT inhibitors (NMTi).

Key Points: 
  • Myricx’s payload platform is based on proprietary potent small molecule NMT inhibitors (NMTi).
  • In the poster presentation Myricx reported data for three NMTi-ADCs in its pipeline.
  • B7-H3-NMTi demonstrated complete and durable tumour regressions in multiple models of aggressive prostate cancer refractory to Topo1i-based ADCs.
  • Myricx CEO, Dr Robin Carr said: “The preclinical data generated by our three NMTi-ADCs give us confidence that the NMTi payload platform has the potential to deliver an important new ADC payload class in the treatment of solid tumours.

NetMind.ai Launches Free BETA for Decentralized AI Model Training Platform

Retrieved on: 
Tuesday, September 26, 2023

NetMind Power is a decentralized AI platform that allows machine learning experts, researchers and software developers to train, fine-tune and inference deep learning models.

Key Points: 
  • NetMind Power is a decentralized AI platform that allows machine learning experts, researchers and software developers to train, fine-tune and inference deep learning models.
  • The platform is built around the concept of Volunteer Computing - a globally distributed network of user contributed GPUs, connected on the blockchain to provide a decentralized computing power network.
  • On the platform itself, users can train their own proprietary models through the UI and this feature is available to use for free during the Beta period.
  • NMT will be used to pay for training and inference on the platform, as well as a means of compensating providers of computing power.